Low-dose KETamine as an Adjunct to MOrphine for Acute Pain in the ED

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2022
The KetMo study is an investigator-initiated, randomized, parallel group, double blinded trial investigating if ketamine as an adjunct to morphine improves pain treatment in the ED. Patients in pain (assessed on NRS, 5 or more) will be randomized to low-dose ketamine or placebo as an adjunct to morphine. Patients with or without prior use of opioids will be randomized separately. The primary outcome will be pain reduction, assessed on NRS, after 10 minutes. Secondary outcomes include pain reduction until 120 minutes after injection of study medicine, need for rescue opioid, side effects and patient- and provider satisfaction.
Epistemonikos ID: ca0a362871d02d23949164d1406f74d23ec814aa
First added on: May 13, 2024